Edition:
United States

People: NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

2.80USD
21 Aug 2018
Change (% chg)

-- (--)
Prev Close
$2.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
160,302
52-wk High
$19.30
52-wk Low
$2.65

Henneman, John 

Mr. John B. Henneman III., is Chief Administrative Officer, Secretary of Newlink Genetics Corporation. Prior to joining the Company, Mr. Henneman served for sixteen years at Integra Life Sciences (“Integra”). He joined Integra in 1998 as General Counsel and Chief Administrative Officer, was appointed Acting Chief Financial Officer in 2007, and assumed that role permanently in 2008. As Chief Financial Officer, he transformed the finance function to accommodate Integra's growth, recruited and developed key leaders in accounting, tax, financial planning and analysis and treasury, and raised almost $1 billion in new debt and equity capital. In April 2014, he was named as Corporate Vice President and Chief Administrative Officer, concurrently with the appointment of a new Chief Financial Officer. During his 16 years at Integra, in addition to his responsibilities as Chief Financial Officer, he led Integra’s business development function, playing a key role in more than 40 acquisitions and alliances, and was responsible at various times for the Company's regulatory affairs, quality systems, clinical affairs, human resources and management of Integra’s surgical instruments business. Integra is not a parent, subsidiary or other affiliate of the Company.

Basic Compensation

Total Annual Compensation, USD 3,080,970
Restricted Stock Awards, USD 936,108
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 4,017,080

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --